In a research study centered around magic mushrooms in Canada, nearly 80% of respondents indicated their support for making psilocybin medically available for patients experiencing distress. Moreover, approximately two-thirds of the Canadian respondents echoed that psilocybin should be legally accessible for those in need.
Besides advocating for easier accessibility to the substance, a notable 84.8 percent of respondents opine that the public health system should bear the costs of such treatments. A majority of Canadians see psilocybin as a feasible alternative, especially for managing end-of-life distress.
[toc]
Key Insights:
- Citizens from Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a valid medical solution for dealing with end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind trials reported immediate and long-lasting advantages, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may encounter feelings of hopelessness, isolation, anxiety, and a sense of loss of meaning and purpose. This type of distress particularly impacts patients with life-threatening diseases, potentially leading to an accelerated desire for death or thoughts of suicide.
Generally, individuals battling terminal diseases or significant life changes are the ones who frequently experience this type of distress. It profoundly affects their mental health and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It could require multiple sessions and may not work for everyone.
The ambiguity regarding the effectiveness of such therapy is a main factor driving many individuals to explore alternative treatments.
Health Canada’s Perspective on Psilocybin as a Therapeutic Option
In the last two decades, initial clinical trials have highlighted the possible advantages of psychedelic substances in addressing complex mental disorders. Specifically, psilocybin has demonstrated its ability to quickly and permanently reduce existential distress in patients nearing end-of-life.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadian Support for Access to Psilocybin
A research article published in the Palliative Care Journal investigates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants had prior experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% support the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys from Canada, England, and Australia. The researchers underscored the uniqueness of their study, as it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Reasons for Canadian Advocacy of Psilocybin Use
An increasing number of Canadians are endorsing the application of psilocybin for treatment, primarily due to evidence presented by reputable research institutions. An additional driving factor is the perceived safety of psilocybin mushrooms for easing existential distress. No severe adverse health effects, such as multi-organ failure, have been reported by subjects in various studies.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The positive effects of the therapy, which can last up to six months or longer, are largely due to mystical experiences that foster a sense of unity and deep-seated emotional enlightenment. |
| New York University Experiment | A random selection of 29 patients received either psilocybin or the active placebo niacin | The results paralleled those of the Johns Hopkins study. People who took psilocybin reported psychological relief and a renewed point of view on life and death. |
| BMC Palliative Care | The study interviewed nineteen participants, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist. The objective was to comprehend how palliative care professionals perceive existential distress and their viewpoint on psychedelic therapy as a potential treatment. | Palliative care practitioners conveyed that psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
Apart from scientific research, personal stories from patients also validate the effectiveness of psilocybin in improving mental health and quality of life.
The Journey of Yokoi
During her therapy, Mio Yokoi, who is battling stage 4 pancreatic cancer, shares a profound experience. She envisions herself on a raft, surrounded by nature, and in the company of imaginative creatures. This vision imbues her with a profound sense of the universe’s interconnectedness and support, providing her with immense peace and validation.
Even with conventional mental health support, Yokoi continued to struggle with severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and imparted a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was battling stage 4 breast cancer that had metastasized to her lungs. She was an administrative supervisor in healthcare and identified herself as an atheist at the time of the study. She was also diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since the therapy, she conveyed that the experiences had infused her beliefs with meaning and substance.
Brenda’s Journey
Brenda, a lady in her sixties, was diagnosed with stage I colon cancer. She had no history of hallucinogen use, and a screening revealed that she met the criteria for Chronic Adjustment Disorder with accompanying Anxiety.
In the course of her therapy sessions, Brenda experienced the sensation of dying twice. These experiences led her to perceive death as a beautiful part of the life cycle, rather than something to fear. She credits the study with starting her healing journey from childhood trauma. Her data reflects this profound change.
She reported reduced anxiety and fear of death, along with an increased sense of spirituality.
Available Magic Mushroom Products in Canada
At present, access to psilocybin capsules and other products designed for managing existential distress and other mental health problems might be limited. However, reliable online dispensaries can provide these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American nations. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which gained recognition in the 1970s. |
| Potency | Moderate potency; suitable for beginners. | Moderate potency as well; great for novices. | High potency; advised for those with a fair to high level of experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Triggers an energizing, long-lasting high, slight visual changes, heightened creativity, euphoria, a mild physical high, fractal images, and a sense of happiness. | Induces profound shamanic experiences, visionary quests, intense mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Alleviating End-of-life Discomfort with Psilocybin Products
End-of-life or existential distress can exert immense pressure on patients nearing the end of their lives. Traditional treatments for this distress can occasionally fall short, prompting a growing support in Canada for easier access to magic mushrooms within the public healthcare system. This increase in public interest could potentially We urge regulatory authorities to consider the potential of magic mushrooms as a practical treatment option. Obtain your psychedelics and mushroom delivery from Shroom Shop Canada.
Frequently Asked Questions
What should patients expect when receiving Psilocybin-Assisted Therapy?
The journey of each patient through Psychedelic-assisted therapy (PAT) can differ significantly. It’s vital to meticulously prepare and follow certain procedures to ensure a positive result. Patients must undergo extensive screening and mental readiness processes prior to consuming the substance.
- Session preparation: Patients go through a thorough assessment process. The therapist discusses the patient’s goals and expectations to set intentions for the session. The therapist also explains the potential impacts and what the patient can expect during the session.
- The Session: Patients receive a controlled dose of the substance in a quiet, comfortable environment to promote relaxation and self-exploration. Throughout this process, the therapist offers constant support and guidance.
- Post-Session Integration Therapy: This form of therapy helps the patient comprehend and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and transformations gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can lead to alterations in perception, mood and thinking, resulting in profound changes in consciousness, emotional revelations, and new viewpoints.
Is psilocybin therapy available to everyone?
Not everyone is a suitable candidate for psilocybin therapy. Patients suffering from certain mental health conditions or existential distress undergo extensive screening to rule out those with a history of psychosis.
Related Articles:
